home / stock / snynf / snynf quote
Last: | $95.45 |
---|---|
Change Percent: | 0.05% |
Open: | $95.45 |
Close: | $95.45 |
High: | $95.45 |
Low: | $95.45 |
Volume: | 357 |
Last Trade Date Time: | 07/02/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$95.45 | $95.45 | $95.45 | $95.45 | $95.45 | 357 | 07-02-2024 |
$95.5 | $0 | $95.5 | $0 | $0 | 50 | 07-01-2024 |
$95.5 | $0 | $95.5 | $0 | $0 | 100 | 06-28-2024 |
$95.5 | $0 | $95.5 | $0 | $0 | 695 | 06-27-2024 |
$95.5 | $94.864 | $95.5 | $95.5 | $94.864 | 412 | 06-26-2024 |
$96 | $95.8 | $96 | $96 | $94.56 | 1,586 | 06-25-2024 |
$96.1044 | $96.578 | $96.1044 | $96.578 | $94.5 | 892 | 06-24-2024 |
$95.28 | $95.28 | $95.28 | $95.28 | $95.28 | 286 | 06-21-2024 |
$92.546 | $92.546 | $92.546 | $92.546 | $92.546 | 544 | 06-20-2024 |
$96.364 | $92.63 | $96.364 | $96.45 | $92.63 | 559 | 06-19-2024 |
$96.364 | $92.63 | $96.364 | $96.45 | $92.63 | 559 | 06-18-2024 |
$94.11 | $94.11 | $94.11 | $94.11 | $94.11 | 882 | 06-17-2024 |
$93.035 | $95.75 | $93.035 | $95.75 | $93 | 1,492 | 06-14-2024 |
$96.0825 | $0 | $96.0825 | $0 | $0 | 50,002 | 06-13-2024 |
$96.0825 | $0 | $96.0825 | $0 | $0 | 8 | 06-12-2024 |
$96.0825 | $0 | $96.0825 | $0 | $0 | 17 | 06-11-2024 |
$96.0825 | $96.7677 | $96.0825 | $96.7677 | $94.678 | 1,778 | 06-10-2024 |
$97.48 | $0 | $97.48 | $0 | $0 | 18 | 06-07-2024 |
$97.48 | $0 | $97.48 | $0 | $0 | 154 | 06-06-2024 |
$97.48 | $97.48 | $97.48 | $97.48 | $97.48 | 998 | 06-05-2024 |
News, Short Squeeze, Breakout and More Instantly...
Audrey Duval Derveloy appointed Global Head of Corporate Affairs, member of Sanofi’s Executive Committee Paris, June 21, 2024 . Audrey Duval Derveloy, a seasoned healthcare industry leader and Sanofi France’s President, has been named Executive Vice President, Global Head ...
ISTH: Sanofi advances leadership in hemophilia with new data for ALTUVIIIO and fitusiran Seven oral presentations across the hemophilia portfolio reinforce Sanofi’s commitment to bring potential first- and best-in-class treatments to the rare blood disorders community Interim r...
Sanofi and Biovac spearhead polio vaccine manufacturing capabilities in Africa Paris, June 20, 2024. Sanofi and Biovac, a Cape Town, South Africa-based biopharmaceutical company, announce today their local manufacturing partnership to produce inactivated polio vaccines (IPV) in Africa. ...